Return to homepagePandemic Pact

Vaccination for Recovered Inpatients with COVID-19 (VATICO)

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 75N91019D00024-P00001-759102000039-1

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2023

  • Known Financial Commitments (USD)

    $15,147,252

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    LAURA MCNAY

  • Research Location

    United States of America

  • Lead Research Institution

    LEIDOS BIOMEDICAL RESEARCH, INC.

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Supportive care, processes of care and management

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase III

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The "SARS-Cov-2 Vaccination Strategies In Previously Hospitalized And Recovered COVID-19 Patients" clinical trial known as "VATICO" is assessing the optimal timing and number of mRNA COVID-19 vaccinations for patients discharged after hospitalization for SARS-CoV-2 infection. This trial is a sub-study of the TICO (Therapeutics for Inpatients with COVID-19) study which is a Phase 3 randomized, blinded, controlled platform trial that allows investigational agents to be added and dropped during the course of the study for efficient testing of new agents against control (i.e., placebo + SOC) within the same trial infrastructure.